As brand­ed drug sales surge, an­a­lysts pre­dict Chi­na mar­ket will re­main 'very at­trac­tive'

The Chi­na mar­ket has long been con­sid­ered a “large and un­tapped op­por­tu­ni­ty” for drug­mak­ers — and ac­cord­ing to Jef­feries an­a­lysts, the for­mer re­mains true.

In a note to in­vestors on Sun­day, an­a­lysts pre­dict­ed Chi­na brand­ed drug sales would reach at least $85 bil­lion by 2030, with the po­ten­tial for even more up­side. Es­ti­mat­ed brand­ed drug sales grew 19% year-over-year in 2021, hit­ting $31.3 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER